Hi-Tech Pharmaceuticals, Inc. v. Hodges Consulting, Inc.
230 F. Supp. 3d 1323
N.D. Ga.2016Background
- Hi‑Tech Pharma sued Hodges (doing business as Double Dragon) alleging patent infringement of U.S. Patent No. 8,084,446 (DHEA compound) and multiple state and federal claims based on Hodges’ SOS‑500 product.
- Hi‑Tech alleges SOS‑500 contains a designer steroid (4‑chloro‑17α‑methyl‑androsta‑1,4‑diene‑3,17‑diol, aka Halovar), a Schedule III substance, but that Hodges marketed SOS‑500 as a “natural/dietary supplement” without disclosing Halovar or warnings.
- Claims: Count I — patent infringement (not challenged in these motions); Counts II–IV — Lanham Act false advertising, Georgia Deceptive Trade Practices Act, and common law unfair competition; Counts V–VII — Georgia RICO predicates based on alleged mail/wire fraud tied to misbranding; Hodges counterclaimed for declaratory judgment of non‑infringement and invalidity.
- Hodges moved to dismiss Counts II–VII arguing FDCA preclusion and that patent/FDCA issues cannot be repackaged into Lanham/UDTPA/RICO claims; Hi‑Tech moved to dismiss Hodges’ patent counterclaims for failure to plead under Twombly/Iqbal.
- The court (Totenberg, J.): (1) allowed Lanham/UDTPA/unfair competition claims to proceed only to the extent they allege deceptive labeling/marketing (e.g., marketing as "natural" or failing to disclose Halovar), but dismissed claims that would require judicial determination that SOS‑500 is a “new drug” or “prescription drug”; (2) dismissed Georgia RICO counts without prejudice for failure to plead predicate acts and proximate cause with particularity and granted leave to amend; (3) dismissed Hodges’ counterclaims for non‑infringement and invalidity under Twombly/Iqbal without prejudice and granted leave to amend.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Whether Lanham/UDTPA/unfair competition claims are precluded by FDCA | Hi‑Tech: claims are permissible because they challenge false/misleading marketing and labeling (e.g., marketed as “natural” while containing Halovar) | Hodges: FDCA precludes these claims; only FDA can enforce drug classification/approval issues | Court: Allowed Lanham/UDTPA/unfair competition claims to proceed only on narrow theories that do not require courts to decide drug classification or FDA approval; dismissed claims premised on SOS‑500 being a "new drug" or "prescription drug" |
| Whether court may decide safety/legality or drug classification under FDCA as part of Lanham claims | Hi‑Tech: court can resolve misleading marketing without resolving FDA classifications | Hodges: court would be intruding on FDA's exclusive authority | Held: Court must avoid making determinations reserved for FDA (e.g., new‑drug status); but can adjudicate whether marketing statements are deceptive without resolving FDCA classification |
| Sufficiency / particularity of Georgia RICO predicates (mail/wire fraud) | Hi‑Tech: RICO predicates are mail/wire fraud based on misbranding and deceptive marketing | Hodges: patent infringement and FDCA violations cannot serve as RICO predicates; Hi‑Tech failed to plead mail/wire fraud and proximate cause with particularity | Held: RICO counts dismissed without prejudice for failure to plead predicate acts and proximate causation with required particularity; leave to amend given |
| Adequacy of Hodges’ patent counterclaims after abrogation of Rule 84/Form 18 | Hodges: statutory recitation of non‑infringement/invalidity suffices | Hi‑Tech: Twombly/Iqbal pleading standard applies post‑Rule 84 abrogation; Hodges pleaded only conclusions | Held: Rule 84/Form 18 safe harbor no longer exists; counterclaims must meet Twombly/Iqbal; Hodges’ counterclaims dismissed without prejudice and leave to amend granted |
Key Cases Cited
- Bell Atlantic Corp. v. Twombly, 550 U.S. 544 (plausibility standard for pleadings)
- Ashcroft v. Iqbal, 556 U.S. 662 (pleading standards; legal conclusions not entitled to assumption of truth)
- POM Wonderful LLC v. Coca‑Cola Co., 573 U.S. 102 (FDCA does not generally preclude Lanham Act claims; but courts must avoid encroaching on FDA’s exclusive domain)
- Am. Dental Ass'n v. Cigna Corp., 605 F.3d 1283 (11th Cir.) (Rule 9(b) particularity for fraud; courts may infer alternative lawful explanations)
- McZeal v. Sprint Nextel Corp., 501 F.3d 1354 (Fed. Cir.) (context on pleading patent claims prior to Rule 84 changes)